Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C
NCT ID: NCT00088504
Last Updated: 2007-12-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
315 participants
INTERVENTIONAL
2004-07-31
2006-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
After the first 24 weeks of treatment, blood tests will be done to see if subjects are responding to treatment. If they are responding, they will continue receiving study treatment in the study for another 24 weeks. If they are not responding, they will stop study treatment. Everyone who is responding will be monitored for 24 weeks after the last dose of medication, to see how long the response lasts.
Evaluations will be performed during the study to look at the safety of the Pegasys®/Copegus® and MMPD or placebo combination, and to see how the combination is working by measuring Hepatitis C Virus in the blood.
At some of the clinical sites performing the study, some subjects may also participate in additional testing to look at the metabolism of the drugs, or to look at the immune response to Hepatitis C virus infection and treatment.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Merimepodib
PEG-Interferon-alpha 2a (Pegasys®)
Ribavirin (Copegus®)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Exclusion Criteria
* You must have been diagnosed with Hepatitis C.
* You must have been treated with pegylated interferon (brand names are Pegasys® or Peg-Intron®) and ribavirin (brand names Rebetol® or Copegus®), for at least 12 weeks. However, you cannot have received more than one course of this combination therapy.
* You must have been a "non-responder" to this treatment, meaning that the virus levels in your blood were always detectable. If you responded to the treatment and then the virus became detectable again (called a "relapse"), you would not be eligible.
* You must not have used illegal drugs, or have a history of significant alcohol use, within the last year before you start the study.
Pegasys® and Copegus® are not recommended for people with some illnesses. You should be in good health in general, with no illnesses that would prevent you from using Pegasys® and Copegus®. If you do not know whether you have any illness or conditions that would prevent you from using these medications, the study doctor or nurse will review your medical history with you to determine this.
If you are a woman who can have children, you must be willing to use two effective methods of birth control during the study and for 6 months after the last dose of the medication. You will have monthly pregnancy tests during this time to make sure you do not become pregnant (This is recommended for anyone taking ribavirin, even when they are not in a clinical study.).
If you are a male, your female partner must not be pregnant, and you both must be willing to use birth control during the time you are in the study, and for 6 months after the last dose of the medication (This is recommended for anyone taking ribavirin, even when they are not in a clinical study.).
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vertex Pharmaceuticals Incorporated
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Vertex Pharmaceuticals Incorporated
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert Kauffman, MD, PhD
Role: STUDY_DIRECTOR
Vertex Pharmaceuticals Incorporated
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Joseph L. Cochran, M.D.
Birmingham, Alabama, United States
Suresh Karne, M.D., Ph.D.
Huntsville, Alabama, United States
Vijayan Balan, M.D.
Phoenix, Arizona, United States
Michael P. DeMicco, M.D.
Anaheim, California, United States
Prahalad B. Jajodia, M.D.
Fresno, California, United States
F. Fred Poordad, M.D.
Los Angeles, California, United States
Ramsey Cheung, M.D.
Palo Alto, California, United States
Myron J. Tong, M.D., Ph.D.
Pasadena, California, United States
Michael T. Bennett, M.D.
San Diego, California, United States
Lisa M. Nyberg, M.D.
San Diego, California, United States
Natalie Bzowej, M.D.
San Francisco, California, United States
Marcelo Kugelmas, M.D.
Englewood, Colorado, United States
Herbert L. Bonkovsky, M.D.
Farmington, Connecticut, United States
Eugene R. Schiff, M.D.
Miami, Florida, United States
Jawahar L. Taunk, M.D.
Palm Harbor, Florida, United States
Arnold L. Lentnek, M.D.
Marietta, Georgia, United States
Ellen B. Hunter, M.D.
Boise, Idaho, United States
Steven L. Flamm, M.D.
Chicago, Illinois, United States
Helen Te, M.D.
Chicago, Illinois, United States
Gerald J. Mingoletti, M.D.
Oak Forest, Illinois, United States
Donald R. Graham, M.D.
Springfield, Illinois, United States
Alvaro G. Koch, M.D.
Lexington, Kentucky, United States
Shaban Faruqui, M.D.
Baton Rouge, Louisiana, United States
Robert M. Be, M.D.
Baton Rouge, Louisiana, United States
Bal Raj Bhandari, M.D.
Monroe, Louisiana, United States
Luis A. Balart, M.D.
New Orleans, Louisiana, United States
Robert Perrillo, M.D.
New Orleans, Louisiana, United States
Michael Epstein, M.D.
Annapolis, Maryland, United States
Natarajan Ravendhran, M.D.
Baltimore, Maryland, United States
Mark Sulkowski, M.D.
Baltimore, Maryland, United States
Milton J. Koch, M.D.
Silver Spring, Maryland, United States
David N. Schwartz, M.D.
Attleboro, Massachusetts, United States
Nezam Afdhal, M.D.
Boston, Massachusetts, United States
Lawton Shick, M.D.
Worcester, Massachusetts, United States
Stuart C. Gordon, M.D.
Detroit, Michigan, United States
John B. Gross, M.D.
Rochester, Minnesota, United States
Jeffrey Rank, M.D.
Saint Paul, Minnesota, United States
Adrian Di Bisceglie, M.D.
St Louis, Missouri, United States
William C. Sloan
Florham Park, New Jersey, United States
Rajendra Prasad Gupta, M.D.
Trenton, New Jersey, United States
David Eric Bernstein, M.D.
Manhasset, New York, United States
Ira M. Jacobson, M.D.
New York, New York, United States
Douglas T. Dieterich, M.D.
New York, New York, United States
Robert Reindollar, M.D.
Charlotte, North Carolina, United States
Andrew Muir, M.D.
Durham, North Carolina, United States
John E. Poulous, M.D.
Fayetteville, North Carolina, United States
Mark E. Jonas, M.D.
Cincinnati, Ohio, United States
Harvey A. Tatum, M.D.
Tulsa, Oklahoma, United States
George Koval, M.D.
Portland, Oregon, United States
Jill P. Smith, M.D.
Hershey, Pennsylvania, United States
Victor Araya, M.D.
Philadelphia, Pennsylvania, United States
Peter J. Molloy, M.D.
Pittsburgh, Pennsylvania, United States
James Scott Strohecker, M.D.
Columbia, South Carolina, United States
Lawrence D. Wruble, M.D.
Memphis, Tennessee, United States
Ronald Pruitt, M.D.
Nashville, Tennessee, United States
Gary L. Davis, M.D.
Dallas, Texas, United States
William M. Lee, M.D.
Dallas, Texas, United States
George G. Burnazian, M.D.
Houston, Texas, United States
Rise Stribling, M.D.
Houston, Texas, United States
Eric J. Lawitz, M.D.
San Antonio, Texas, United States
Daniel Pambianco, M.D.
Charlottesville, Virginia, United States
Vinod Rustgi, M.D.
Fairfax, Virginia, United States
Mitchell Shiffman, M.D.
Richmond, Virginia, United States
Robert A. Wohlman, M.D.
Bellevue, Washington, United States
Robert L. Carithers, M.D.
Seattle, Washington, United States
David Winters McEniry, M.D.
Tacoma, Washington, United States
Michael F. Lyons II, M.D.
Tacoma, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Rustgi VK, Lee WM, Lawitz E, Gordon SC, Afdhal N, Poordad F, Bonkovsky HL, Bengtsson L, Chandorkar G, Harding M, McNair L, Aalyson M, Alam J, Kauffman R, Gharakhanian S, McHutchison JG; MErimepodib TRiple cOmbination Study Group. Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders. Hepatology. 2009 Dec;50(6):1719-26. doi: 10.1002/hep.23204.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VX03-497-205
Identifier Type: -
Identifier Source: org_study_id